Kymera Therapeutics Inc (KYMR) USD0.0001
Sell:$43.65Buy:$45.20
$0.73
(1.61%)
- This stock can be held in a
Stocks and Shares ISA$0.73
(1.61%)$0.73
(1.61%)Company Information
About this company
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Key people
Key facts
- EPICKYMR
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS5015751044
- Market cap$3.17bn
- Employees208
- Shares in issue70.16m
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.